
Core Insights - BiomX anticipates reporting significant results in 2025 for two clinical assets, BX004 and BX211, from its phage therapy pipeline [1][2] - The company has successfully converted Series X Non-Voting Convertible Preferred Stock into common stock following a stockholder vote [1][6] - BiomX will host a conference call and webcast to discuss its financial results and corporate updates [1][12] Clinical Program Updates - BX004 is a fixed phage cocktail targeting chronic pulmonary infections in cystic fibrosis patients, with positive Phase 1b/2a trial results presented at major conferences [3][4] - In the BX004 arm, 14.3% of patients achieved negative sputum cultures for P. aeruginosa after 10 days, compared to 0% in the placebo group [4] - A Phase 2b trial for BX004 is expected to start, with results anticipated in Q3 2025 [5][14] - BX211 is a personalized phage treatment for diabetic foot osteomyelitis, currently in a Phase 2 trial with initial results expected in Q1 2025 [5][16] Business Update - BiomX's stockholders approved the conversion of Series X Preferred Stock into common stock, resulting in the addition of 109,152,000 shares to the outstanding share count [6] - The company received an Acceptance Letter from NYSE American, granting until November 23, 2025, to regain compliance with listing standards [7] Financial Results - As of June 30, 2024, BiomX reported a cash balance of $32.7 million, an increase from $30.7 million a year prior, primarily due to a $50 million financing [8] - Research and development expenses for Q2 2024 were $6.9 million, up from $3.8 million in Q2 2023, reflecting increased clinical trial preparations [9] - General and administrative expenses rose to $2.8 million in Q2 2024 from $2.3 million in Q2 2023, attributed to the merger's full consolidation [10] - The company reported a net income of $4.5 million for Q2 2024, a significant improvement from a net loss of $6.4 million in Q2 2023 [11]